<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839889</url>
  </required_header>
  <id_info>
    <org_study_id>D3820C00041</org_study_id>
    <nct_id>NCT02839889</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)</brief_title>
  <official_title>A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospice of Henderson County, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospice of Henderson County, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if naloxegol can be used in the treatment of
      opioid-induced constipation in patients with cancer and pain. This phase 4 study consists of
      a two week randomized double blind period followed by a two week open-label period.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped due to challenges recruiting eligible patients.
  </why_stopped>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">January 11, 2018</completion_date>
  <primary_completion_date type="Actual">January 11, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numerical Rating Scale (NRS) for Pain Change From Baseline</measure>
    <time_frame>Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.</time_frame>
    <description>Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily Opioid Use Change From Baseline</measure>
    <time_frame>Assessed from screening through study completion, approximately 6 weeks.</time_frame>
    <description>Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate there was a need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events Associated With Blood Laboratory Result Changes From Baseline</measure>
    <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
    <description>Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram QTC Interval</measure>
    <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
    <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) QTC interval data will be derived by subtracting the baseline value from the final assessment data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram Heart Rate</measure>
    <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
    <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) heart rate data will be derived by subtracting the baseline value from the final assessment data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure</measure>
    <time_frame>Change from Baseline in systolic blood pressure through study completion, approximately 6 weeks.</time_frame>
    <description>Change from Baseline in systolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Diastolic Blood Pressure</measure>
    <time_frame>Change from Baseline in diastolic blood pressure through study completion, approximately 6 weeks.</time_frame>
    <description>Change from Baseline in diastolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Respiratory Rate</measure>
    <time_frame>Change from Baseline in respiratory rate through study completion, approximately 6 weeks.</time_frame>
    <description>Change from Baseline in respiratory rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate</measure>
    <time_frame>Change from Baseline in pulse rate through study completion, approximately 6 weeks.</time_frame>
    <description>Change from Baseline in pulse rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rescue Free Bowel Movements (RFBM) Responder Rate</measure>
    <time_frame>Assessed from Baseline through Study Completion, approximately 6 weeks.</time_frame>
    <description>Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7. RFBM rate calculated from post baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Post-dose Rescue Free Laxation</measure>
    <time_frame>First dose date to first post-dose rescue free bowel movement</time_frame>
    <description>Time (in hours) to first post-dose rescue free bowel movement minus first dose date and time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bristol Stool Scale (BSS) Score</measure>
    <time_frame>Assessed from baseline through Study Completion, approximately 6 weeks.</time_frame>
    <description>The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes.
Bristol Stool Scale (BSS) Score calculated by the sum of daily BSS scores divided by the number of bowel movements that occurred from baseline to study completion. Change from Baseline calculated as the Baseline value minus the post-baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Symptoms (PAC-SYM)</measure>
    <time_frame>day 1, day 15, day 29</time_frame>
    <description>The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.
Change from baseline in mean values calculated as post-baseline value minus baseline value for each scale, and for total. Post-baseline values defined as the mean of day 15 and day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Constipation Quality of Life (PAC-QOL)</measure>
    <time_frame>day 1, day 15, day 29</time_frame>
    <description>The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Items 1-4 measure physical discomfort (subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.
Change from baseline in mean values calculated as post-baseline value minus baseline value for each subscale, and for total. Post-baseline values defined as the mean of day 15 and day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Straining Question With Each Bowel Movement</measure>
    <time_frame>Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.</time_frame>
    <description>Degree of straining scale is 1 to 5 with 1 being &quot;not at all&quot; and 5 being &quot;an extreme amount&quot;. Lower scores are better and higher scores are worse.
Change from baseline in mean values calculated as the post baseline value minus the baseline. Degree of Straining scale change from baseline mean scores calculated from baseline to study completion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Evacuation Question With Each Bowel Movement</measure>
    <time_frame>Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.</time_frame>
    <description>Change from Baseline in mean values calculated as the post baseline value minus the baseline. The post baseline value is the percentage of days from baseline to study completion with at least one complete bowel evacuation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cancer</condition>
  <condition>Constipation</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for two weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxegol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxegol 25mg tablets once daily for two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxegol</intervention_name>
    <description>Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
    <arm_group_label>Naloxegol</arm_group_label>
    <other_name>Movantik</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for two weeks, followed by two week open-label period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged 18 or older: Women of child bearing potential must have a negative
             urine pregnancy test during the Screening/Opioid Induced Constipation (OIC)
             Confirmation/Baseline period, a history of no sexual activity or consistent use of an
             effective birth control method for at least 12 weeks prior to the study, and agreement
             that no sexual activity or the method of birth control will be continued during the
             study and for a period of 8 weeks after it ends; male patients who are sexually active
             must agree to use a barrier method of contraception (condom with spermicide) from the
             first dose of Investigational Product until 12 weeks after their last dose

          -  Able to follow instructions in English, give informed consent and to answer patient
             reported outcomes (PRO) questions by himself/herself; the patient will provide written
             informed consent before initiation of any study-related procedures

          -  Active cancer of any type with an investigator-estimated life expectancy ≥ 8 weeks and
             a Palliative Performance Status scale score ≥ 30%

          -  Patients receiving concurrent chemotherapy must have received and recovered from a
             minimum of 1 cycle of the current chemotherapy regimen upon consenting to the study
             and be considered stable in the opinion of the investigator

          -  Chronic cancer-related pain, defined as pain for a minimum of ≥2 weeks which on review
             by the investigator, can be attributed to the neoplasm or its treatment

          -  Daily treatment with an opioid drug which is taken at a dose equal to or greater than
             20 mg morphine or its equivalent for at least one week, with no expectation of a
             decrease greater than 25% or an increase greater than 100% during the study period.

          -  Patients may or may not be on a stable laxative regimen, defined as daily use at a
             stable dose for &gt;7 days; if the patient is taking a stable dose, he or she must be
             willing to remain on that regimen for the 7 day confirmation period without titration
             or adjustments.

        History of constipation, defined through history and through participation in the
        Screening/OIC Confirmation/Baseline period:

          -  Patient history must include 2 or more of the following during defecations occurring
             in the two weeks prior to screening:

          -  &lt;3 spontaneous bowel movements per week

          -  hard/lumpy stools (Bristol Stool Scale Type 1 or 2) in more than 25% of defecations

          -  sensation of incomplete evacuation in more than 25% of defecations

          -  sensation of anorectal obstruction in more than 25% of defecations

          -  Straining during more than 25% of defecations

        Note: (spontaneous bowel movements (SBMs) are defined as not using a laxative if not
        already taking daily laxatives, or if taking daily laxatives, not using an additional
        laxative).

          -  Confirmation during the 7-day OIC confirmation period must include at least 2 or more
             of the following symptoms:

          -  &lt;3 SBMs per week

          -  hard/lumpy stools (Bristol Stool Scale Type 1 or 2) in more than 25% of defecations

          -  sensation of incomplete evacuation in more than 25% of defecations

          -  sensation of anorectal obstruction in more than 25% of defecations

          -  Straining during more than 25% of defecations

        Exclusion Criteria:

          -  Cancer-related/medical comorbidity-related

               -  Patients with a past or current history of intra-abdominal neoplasm AND clinical
                  findings that, on review by the investigator, may increase the risk of bowel
                  perforation

               -  An active condition associated with clinically significant brain pathology,
                  including known brain metastases, meningeal metastases, past traumatic brain
                  injury, multiple sclerosis, uncontrolled epilepsy with signs or symptoms of
                  compromised blood brain barrier

               -  Patients expected to undergo a first course of a chemotherapy regimen during the
                  study period, patients who received a vinca alkaloid within 2 months, patients
                  who have any history of vinca-associated GI autonomic neuropathy and/or
                  constipation, or patients receiving a chemotherapy regimen including a
                  VEGF-inhibitor (e.g., bevacizumab, sorafenib).

               -  Requiring radiation therapy between the diaphragm and pelvis 2 weeks prior to
                  Visit 1 (screening) and/or during the study

               -  Any other significant and/or progressive condition (medical, neurological,
                  psychiatric or metabolic) or symptom that could increase the risk of
                  participation in the study or affect the interpretation of study data as
                  determined by the investigator (e.g., uncontrolled hypothyroidism, inadequately
                  controlled clinical depression, poorly controlled seizure disorder)

               -  Hemorrhagic diathesis

               -  Expected to have a surgical procedure requiring general anesthesia during the
                  study period

          -  Other gastrointestinal disorders

               -  Medical conditions and treatments, which in the judgment of the investigator, may
                  be associated with diarrhea, intermittent loose stools, or constipation, (e.g.,
                  active diverticular disease, peritonitis of any cause, inflammatory bowel
                  disease, active irritable bowel syndrome, chronic idiopathic constipation).

               -  Any conditions that could affect the absorption or metabolism of the study drug
                  (e.g., malabsorption syndrome, severe liver disease) as judged by the
                  investigator

               -  Evidence of fecal impaction either by physical or x-ray exam

               -  Known or suspected mechanical GI obstruction

               -  Current peritoneal catheter for intra-peritoneal chemotherapy or dialysis

               -  Fecal ostomy

               -  History of fecal incontinence

               -  History of bowel surgery within 60 days of the screening period

               -  Any other potential non-opioid cause of bowel dysfunction that in opinion of
                  investigator might be a contributor to the constipation

          -  Pain-related

               -  Receiving opioid medication on less than daily dosing schedule only

               -  Severe background pain (eg, typical average daily pain intensity rating of 8 to
                  10 on an 11-point NRS) refractory opioid therapy

          -  Any of the following findings or conditions between the enrollment and randomization
             visits:

               -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;2.5 x
                  upper limit normal (ULN) and/or serum bilirubin &gt;2 x ULN (unless elevation is due
                  to Gilbert's syndrome)

               -  Calculated Creatinine clearance &lt;30 ml/min

               -  A Fridericia corrected QT interval (QTcF) &gt; 500 msec at screening, history of
                  myocardial infarction within 6 months before randomization, symptomatic
                  congestive heart failure despite treatment, unstable angina, or symptomatic
                  peripheral vascular disease

               -  Active substance or alcohol use that, in the opinion of the investigator, may
                  compromise patient's ability to comply with the study instructions

               -  Use of prohibited medications as listed in Section 5.5

               -  Pregnancy or lactation

               -  Known history of intolerance or hypersensitivity to alvimopan, methylnaltrexone,
                  or other peripherally acting opioid antagonists or to any other component in the
                  tablets

               -  Involvement in the planning and/or conduct of the study (applies to AstraZeneca
                  staff, staff at the study site, and third-party vendors)

               -  Any receipt of an investigational medication within 30 days of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Bull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospice of Henderson County, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MJHS Institute for Innovation in Palliative Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospice of Henderson County, Inc</name>
      <address>
        <city>Flat Rock</city>
        <state>North Carolina</state>
        <zip>28731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospice of the Western Reserve, Inc.</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <results_first_submitted>November 21, 2018</results_first_submitted>
  <results_first_submitted_qc>February 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>February 8, 2019</last_update_submitted>
  <last_update_submitted_qc>February 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospice of Henderson County, Inc.</investigator_affiliation>
    <investigator_full_name>Janet Bull</investigator_full_name>
    <investigator_title>Chief Medical Officer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxegol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02839889/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This multi center was conducted at 3 sites in the US. Enrollment to the study was stopped due to recruitment challenges and no new patients have been screened as of January 2018. 5 patients were randomized across the 2 treatment groups.</recruitment_details>
      <pre_assignment_details>To confirm eligibility participants underwent a 7 day baseline assessment/OIC confirmation period. 12 patients provided consent for this study, however 7 did not fulfill eligibility criteria during the 7 day baseline period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
        </group>
        <group group_id="P2">
          <title>Naloxegol</title>
          <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Open-Label Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
        </group>
        <group group_id="B2">
          <title>Naloxegol</title>
          <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Numerical Rating Scale (NRS) for Pain</title>
          <description>Baseline Numerical Rating Scale (NRS) for Pain during the OIC Confirmation Period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" lower_limit="5.1" upper_limit="6.3"/>
                    <measurement group_id="B2" value="6.2" lower_limit="5.4" upper_limit="7.1"/>
                    <measurement group_id="B3" value="6.0" lower_limit="5.1" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Electrocardiogram QTC Interval</title>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="430.8" lower_limit="423" upper_limit="438.5"/>
                    <measurement group_id="B2" value="414.5" lower_limit="381.6" upper_limit="447"/>
                    <measurement group_id="B3" value="421" lower_limit="381.6" upper_limit="447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Electrocardiogram Heart Rate</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" lower_limit="80" upper_limit="84"/>
                    <measurement group_id="B2" value="79" lower_limit="66" upper_limit="98"/>
                    <measurement group_id="B3" value="80.2" lower_limit="66" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Daily Opioid Use</title>
          <units>morphine milligram equivalents per day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300" lower_limit="240" upper_limit="360"/>
                    <measurement group_id="B2" value="126.5" lower_limit="40" upper_limit="300"/>
                    <measurement group_id="B3" value="196" lower_limit="40" upper_limit="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.5" lower_limit="110" upper_limit="157"/>
                    <measurement group_id="B2" value="118" lower_limit="88" upper_limit="150"/>
                    <measurement group_id="B3" value="124.2" lower_limit="88" upper_limit="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Diastolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85" lower_limit="76" upper_limit="94"/>
                    <measurement group_id="B2" value="71.3" lower_limit="56" upper_limit="96"/>
                    <measurement group_id="B3" value="76.8" lower_limit="56" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Pulse Rate</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81" lower_limit="78" upper_limit="84"/>
                    <measurement group_id="B2" value="79" lower_limit="60" upper_limit="104"/>
                    <measurement group_id="B3" value="79.8" lower_limit="60" upper_limit="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Bristol Stool Scale score</title>
          <description>The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.91" lower_limit="2.17" upper_limit="5.64"/>
                    <measurement group_id="B2" value="1.94" lower_limit="1.75" upper_limit="2.33"/>
                    <measurement group_id="B3" value="2.73" lower_limit="1.75" upper_limit="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Respiratory Rate</title>
          <units>breaths per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="12" upper_limit="16"/>
                    <measurement group_id="B2" value="15.3" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="B3" value="14.8" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Degree of Straining</title>
          <description>Degree of straining scale measures the amount of straining during a bowel movement. The scale is 1 to 5 with 1 being &quot;not at all&quot; and 5 being &quot;an extreme amount&quot;. Lower scores are better and higher scores are worse.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.21" lower_limit="1.91" upper_limit="2.5"/>
                    <measurement group_id="B2" value="2.06" lower_limit="1.17" upper_limit="3.25"/>
                    <measurement group_id="B3" value="2.12" lower_limit="1.17" upper_limit="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Complete Evacuation with Bowel Movements</title>
          <units>% of days with complete evacuation</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.3" lower_limit="28.6" upper_limit="50"/>
                    <measurement group_id="B2" value="41.7" lower_limit="25" upper_limit="62.5"/>
                    <measurement group_id="B3" value="40.7" lower_limit="25" upper_limit="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Patient Assessment of Constipation Symptom Assessments (PAC-SYM)</title>
          <description>The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Abdominal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="5" upper_limit="8"/>
                    <measurement group_id="B2" value="8" lower_limit="7" upper_limit="9"/>
                    <measurement group_id="B3" value="7.4" lower_limit="5" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B2" value="3.3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B3" value="2.8" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" lower_limit="6" upper_limit="9"/>
                    <measurement group_id="B2" value="8" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="B3" value="7.8" lower_limit="3" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16" lower_limit="12" upper_limit="20"/>
                    <measurement group_id="B2" value="19.3" lower_limit="13" upper_limit="28"/>
                    <measurement group_id="B3" value="18" lower_limit="12" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Patient Assessment of Constipation (PAC-QOL)</title>
          <description>The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Each item is scored 0-4. Items 1-4 measure physical discomfort (total subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Physical Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="7" upper_limit="9"/>
                    <measurement group_id="B2" value="4.7" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="B3" value="6" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosocial discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" lower_limit="6" upper_limit="22"/>
                    <measurement group_id="B2" value="4.3" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="B3" value="8.2" lower_limit="0" upper_limit="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worries/concerns</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" lower_limit="11" upper_limit="23"/>
                    <measurement group_id="B2" value="15.3" lower_limit="8" upper_limit="25"/>
                    <measurement group_id="B3" value="16" lower_limit="8" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" lower_limit="5" upper_limit="6"/>
                    <measurement group_id="B2" value="3.3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="B3" value="4.2" lower_limit="2" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" lower_limit="31" upper_limit="58"/>
                    <measurement group_id="B2" value="27.7" lower_limit="13" upper_limit="46"/>
                    <measurement group_id="B3" value="34.4" lower_limit="13" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numerical Rating Scale (NRS) for Pain Change From Baseline</title>
        <description>Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.</description>
        <time_frame>Assessed from screening/Opioid Induced Constipation (OIC) Confirmation period through study completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Numerical Rating Scale (NRS) for Pain Change From Baseline</title>
          <description>Change from baseline in mean daily NRS (Numerical Rating Scale) values will be calculated as the post-baseline value minus the baseline. Baseline NRS is the mean daily NRS values recorded during the Opioid Induced Constipation (OIC) Confirmation period. Numeric Rating Scale is 0-10. 0 is no pain and 10 is worst possible pain. Lower values are a better outcome and higher values are a worse outcome. Post-baseline values were calculated as the mean of NRS scores during visits 2-4.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" lower_limit="0.3" upper_limit="1"/>
                    <measurement group_id="O2" value=".33" lower_limit="-0.4" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Daily Opioid Use Change From Baseline</title>
        <description>Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate there was a need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.</description>
        <time_frame>Assessed from screening through study completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Opioid Use Change From Baseline</title>
          <description>Change from baseline in mean daily opioid dose will be calculated as the post-baseline value minus the baseline value. Positive changes from baseline indicate there was a need to increase the opioid dose. Baseline daily opioid dose is the mean daily opioid dose recorded during the Opioid Induced Constipation (OIC) Confirmation period.</description>
          <units>morphine milligram equivalents per day</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1144" lower_limit="0" upper_limit="2288"/>
                    <measurement group_id="O2" value="20" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events Associated With Blood Laboratory Result Changes From Baseline</title>
        <description>Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.</description>
        <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
        <population>All abnormal lab values were deemed not clinically significant by Investigators. Therefore, changes did not meet the criteria for an adverse event and changes were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Associated With Blood Laboratory Result Changes From Baseline</title>
          <description>Changes from Baseline to Visit 3 (approximately Day 15) for all patients will be calculated as the post-baseline test value minus the baseline test value.</description>
          <population>All abnormal lab values were deemed not clinically significant by Investigators. Therefore, changes did not meet the criteria for an adverse event and changes were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Electrocardiogram QTC Interval</title>
        <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) QTC interval data will be derived by subtracting the baseline value from the final assessment data.</description>
        <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram QTC Interval</title>
          <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) QTC interval data will be derived by subtracting the baseline value from the final assessment data.</description>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.8" lower_limit="-61.6" upper_limit="12"/>
                    <measurement group_id="O2" value="-6.9" lower_limit="-17" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Electrocardiogram Heart Rate</title>
        <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) heart rate data will be derived by subtracting the baseline value from the final assessment data.</description>
        <time_frame>Change from Baseline at End of Double Blind Phase (Visit 3, approximately day 15)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Electrocardiogram Heart Rate</title>
          <description>Changes from Baseline to Visit 3 (approximately Day 15) for Electrocardiogram (ECG) heart rate data will be derived by subtracting the baseline value from the final assessment data.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="7" upper_limit="11"/>
                    <measurement group_id="O2" value="10" lower_limit="2" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure</title>
        <description>Change from Baseline in systolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
        <time_frame>Change from Baseline in systolic blood pressure through study completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure</title>
          <description>Change from Baseline in systolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" lower_limit="-30.3" upper_limit="9.7"/>
                    <measurement group_id="O2" value="-8.8" lower_limit="-19" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Diastolic Blood Pressure</title>
        <description>Change from Baseline in diastolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
        <time_frame>Change from Baseline in diastolic blood pressure through study completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Diastolic Blood Pressure</title>
          <description>Change from Baseline in diastolic blood pressure at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" lower_limit="-20" upper_limit="-1"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-9.3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Respiratory Rate</title>
        <description>Change from Baseline in respiratory rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
        <time_frame>Change from Baseline in respiratory rate through study completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Respiratory Rate</title>
          <description>Change from Baseline in respiratory rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
          <units>breaths per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="-2" upper_limit="5.3"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-0.7" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate</title>
        <description>Change from Baseline in pulse rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
        <time_frame>Change from Baseline in pulse rate through study completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate</title>
          <description>Change from Baseline in pulse rate at post baseline (visits 2, 3, 4) will be derived as the value at the visit minus the baseline value for the same assessment. The post-baseline values were calculated as a mean of values from visits 2 through 4.</description>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="3.7" upper_limit="5.3"/>
                    <measurement group_id="O2" value="10.3" lower_limit="5.3" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rescue Free Bowel Movements (RFBM) Responder Rate</title>
        <description>Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7. RFBM rate calculated from post baseline period.</description>
        <time_frame>Assessed from Baseline through Study Completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Rescue Free Bowel Movements (RFBM) Responder Rate</title>
          <description>Daily diary data will be used to identify RFBMs. The weekly RFBM frequency within each time period will be calculated as: (Total number of RFBMs during the time period of interest/number of days) x 7. RFBM rate calculated from post baseline period.</description>
          <units>RFBMs/days *7</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" lower_limit="3.5" upper_limit="12.79"/>
                    <measurement group_id="O2" value="3.82" lower_limit="1.59" upper_limit="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Post-dose Rescue Free Laxation</title>
        <description>Time (in hours) to first post-dose rescue free bowel movement minus first dose date and time.</description>
        <time_frame>First dose date to first post-dose rescue free bowel movement</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Post-dose Rescue Free Laxation</title>
          <description>Time (in hours) to first post-dose rescue free bowel movement minus first dose date and time.</description>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.3" lower_limit="17.96" upper_limit="28.58"/>
                    <measurement group_id="O2" value="33.5" lower_limit="3.67" upper_limit="67.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bristol Stool Scale (BSS) Score</title>
        <description>The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes.
Bristol Stool Scale (BSS) Score calculated by the sum of daily BSS scores divided by the number of bowel movements that occurred from baseline to study completion. Change from Baseline calculated as the Baseline value minus the post-baseline value.</description>
        <time_frame>Assessed from baseline through Study Completion, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Bristol Stool Scale (BSS) Score</title>
          <description>The Bristol Stool Scale classifies the type of bowel movement on a scale from 1-7, based on the appearance of stool. 1 indicates severe constipation, 2 indicates mild constipation, 3-4 indicate a normal bowel movement, 5 indicates that the patient is lacking dietary fiber, 6 indicates mild diarrhea, and 7 indicates severe diarrhea. A better score would trend toward the middle of the scale (ranges 3-4), while scores at either end of the scale correspond to worse outcomes.
Bristol Stool Scale (BSS) Score calculated by the sum of daily BSS scores divided by the number of bowel movements that occurred from baseline to study completion. Change from Baseline calculated as the Baseline value minus the post-baseline value.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.06" lower_limit="-.4" upper_limit=".28"/>
                    <measurement group_id="O2" value="2.37" lower_limit="1.51" upper_limit="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Constipation Symptoms (PAC-SYM)</title>
        <description>The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.
Change from baseline in mean values calculated as post-baseline value minus baseline value for each scale, and for total. Post-baseline values defined as the mean of day 15 and day 29.</description>
        <time_frame>day 1, day 15, day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Constipation Symptoms (PAC-SYM)</title>
          <description>The PAC-SYM is divided into three subscales. Each item is scored 0-4. Items 1-4 measure abdominal symptoms (total subscale range 0-16), items 5-7 measure rectal symptoms (total subscale score 0-12), and items 8-12 measure stool symptoms (total subscale range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total construct score is generated by summing the scores of the subscales. This total score ranges from 0-48, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.
Change from baseline in mean values calculated as post-baseline value minus baseline value for each scale, and for total. Post-baseline values defined as the mean of day 15 and day 29.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abdominal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value=".5" lower_limit="-2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="1" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.2" lower_limit="-1.5" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stool Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".5" lower_limit="-0.5" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-.2" lower_limit="-1.5" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="2.5" upper_limit="3"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-3.5" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Constipation Quality of Life (PAC-QOL)</title>
        <description>The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Items 1-4 measure physical discomfort (subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.
Change from baseline in mean values calculated as post-baseline value minus baseline value for each subscale, and for total. Post-baseline values defined as the mean of day 15 and day 29.</description>
        <time_frame>day 1, day 15, day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Constipation Quality of Life (PAC-QOL)</title>
          <description>The PAC-QOL is a 28-item questionnaire divided into 4 subscales. Items 1-4 measure physical discomfort (subscale range 0-16), 5-12 measure psychosocial discomfort (range 0-32), 13-23 measure worries/concerns (range 0-44), and 24-28 measure satisfaction (range 0-20). For each subscale, lower scores are better and higher scores are worse.
The total score is generated by summing the scores of the subscales. This total score ranges from 0-112, with lower scores corresponding to better outcomes, and higher scores corresponding to worse outcomes.
Change from baseline in mean values calculated as post-baseline value minus baseline value for each subscale, and for total. Post-baseline values defined as the mean of day 15 and day 29.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.25" lower_limit="-1.5" upper_limit="-1"/>
                    <measurement group_id="O2" value="0.17" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychosocial Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-9" upper_limit="7"/>
                    <measurement group_id="O2" value="6" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worries/concerns</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-3.5" upper_limit="6.5"/>
                    <measurement group_id="O2" value="1.17" lower_limit="-1.5" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="3.83" lower_limit="2" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" lower_limit="-12" upper_limit="17.5"/>
                    <measurement group_id="O2" value="11.17" lower_limit="5.5" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Degree of Straining Question With Each Bowel Movement</title>
        <description>Degree of straining scale is 1 to 5 with 1 being &quot;not at all&quot; and 5 being &quot;an extreme amount&quot;. Lower scores are better and higher scores are worse.
Change from baseline in mean values calculated as the post baseline value minus the baseline. Degree of Straining scale change from baseline mean scores calculated from baseline to study completion.</description>
        <time_frame>Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Straining Question With Each Bowel Movement</title>
          <description>Degree of straining scale is 1 to 5 with 1 being &quot;not at all&quot; and 5 being &quot;an extreme amount&quot;. Lower scores are better and higher scores are worse.
Change from baseline in mean values calculated as the post baseline value minus the baseline. Degree of Straining scale change from baseline mean scores calculated from baseline to study completion.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".6" lower_limit="-.31" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-.35" lower_limit="-.67" upper_limit=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Evacuation Question With Each Bowel Movement</title>
        <description>Change from Baseline in mean values calculated as the post baseline value minus the baseline. The post baseline value is the percentage of days from baseline to study completion with at least one complete bowel evacuation.</description>
        <time_frame>Assessed at baseline through Study Completion with each bowel movement, approximately 6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
          </group>
          <group group_id="O2">
            <title>Naloxegol</title>
            <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Evacuation Question With Each Bowel Movement</title>
          <description>Change from Baseline in mean values calculated as the post baseline value minus the baseline. The post baseline value is the percentage of days from baseline to study completion with at least one complete bowel evacuation.</description>
          <units>% of days with complete evacuation</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.92" lower_limit="21.43" upper_limit="22.41"/>
                    <measurement group_id="O2" value="7.7" lower_limit="-11.36" upper_limit="79.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Occurrences from Baseline through study completion, approximately 6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo once daily for two weeks
Placebo: Placebo once daily for two weeks, followed by two week open-label period</description>
        </group>
        <group group_id="E2">
          <title>Naloxegol</title>
          <description>Naloxegol 25mg tablets once daily for two weeks
Naloxegol: Naloxegol 25mg tablets for two weeks, followed by a two week open-label period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>worsening constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>abdominal cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>abdominal distention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>increased abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>increased back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bladder spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to significant recruitment challenges enrollment was stopped. Only 5 patients were randomized (less than 12% of expected). There was insufficient data to perform the protocol specified analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Janet Bull, MD</name_or_title>
      <organization>Four Seasons Compassion for Life</organization>
      <phone>8286926178 ext 302</phone>
      <email>jbull@fourseasonscfl.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

